Shanghai BociMed Pharmaceutical Co Ltd

  • Room 1002, 1006, No. 781, CaiLun Road
  • Shanghai
  • CHINA
  • China
  • 201 203 (map)

  • Tel: +86 02168861631
  • Fax: +86 02168861631
  • Website: www.bocimed.com

Contacts

  • Chrissy Chen, Marketing Assistant
  •  
  • Number of Employees: Unavailable

Shanghai BociMed Pharmaceutical Co., Ltd. is a high-tech enterprise which is devoted to providing technical service for innovative and generic drugs. The company gathers experienced PhDs and Masters from Pharmaceutical University, Drug Institutes, Institute of Organic Chemistry and other research institutions. The R&D center includes synthesis, finished formulation, analysis and registration departments. Based on close cooperation between teams and clear R&D process, the center possesses excellent R&D ability.

The R&D center of the company is located in Zhangjiang High-Tech Park with pronounced technical atmosphere, and occupies over 3000m2, and has contract factories in Shandong and Jiangsu. The facilities for synthesis, analysis and finished formulation R&D includes 50-100L reactor, high pressure hydrogenation reactor, 20L rotary evaporator, low-temperature circulate cooling facility, 20 HPLC equipments (imported full-automatic injection, equipped with fluorescence detector, DAD and microtiter loop), Headspace Shimadzu GC, ultraviolet spectrophotometer, dissolution tester, potentiometric titrator, fluidized bed, Efficient wet granulating machine, dry type granulator, rotary pelleting machine, freeze dryer and etc.

The company has applied for 5 invention patents, and has got 2 authorized; has finished one “Technical Breakthrough” program organized by Science and Technology Commission of Shanghai Municipality and gained Innovation Fund for Small and Medium- sized Enterprises of Science and Technology; and has obtained two National Science and Technology Major Projects support. 16 products have been given manufacture licenses. 7 new drugs belong to 3.1 class have been under clinical trials. 13 products belong to 3+3 class, and 6 products belong to 3+6 class, have been finished with pro-clinical study, and have been submitted to CFDA for manufacture licenses. 12 products belong to 3+3 class, and 8 products belong to 3+6 class have been under R&D. One National Science and Technology Major Project is in progress.

Taking domestic market as basis, the company is exploring the overseas market as well, and has cooperated with the customers from India, Korea and Spain for API and CRO.

Applegate PRO

Support resources

Call Applegate +44 (0)345 600 7177